Ask Your Provider About Cannabis: Increasing Nurse Practitioner Knowledge and Confidence

Cannabis Cannabinoid Res. 2022 Oct;7(5):700-705. doi: 10.1089/can.2021.0061. Epub 2021 Aug 24.

Abstract

Introduction: Nurse practitioners (NPs) are authorizing providers for medical cannabis in many states, and may serve as a primary care clinician. We report findings from a nationally distributed 2-h continuing education (CE) module aimed to improve knowledge, confidence, and willingness to communicate with patients about cannabis. Methods: Data were electronically obtained from the CE platform pre- and post-test (n=289) and a follow-up survey sent within 3 months postcompletion (n=184, 63%). Pre- and post-testing assessed cannabis pharmacodynamics, law, evidence-based use, metabolism, pharmacokinetics, laboratory testing, adverse reactions, and drug-drug interactions. The subsequent survey asked about changes in practice behavior, including willingness and self-identified recommendations for use. Quantitative and qualitative descriptive analysis and repeated-measures analysis of variance were used to analyze CE impact. Results: Significant improvement in scores was noted from pretest to post-test for all content with a mean improvement of 39.3% (95% CI: 30.6-47.9%). The greatest increases were for metabolism, pharmacokinetics, and drug-drug interaction content. At follow-up, 52.2% reported that the CE changed their attitudes about cannabis and although 86% had rarely or never applied it yet in practice, 92% reported they were now likely to inquire about cannabis use in their patients and 84% were likely to counsel patients about it. Although self-identified recommendations overlapped by conditions, some were unique to CBD (complex regional pain syndrome, migraine, mood disorder, smoking cessation) and THC products (appetite, cachexia, depression, fibromyalgia, HIV, seizure disorder, stress, and weight loss). Pain was the most common condition for recommendation of both CBD and THC, followed by anxiety and arthritis. Conclusions: NPs gained key knowledge about cannabis, which may impact patient care and prescribing practices. The educational module resulted in more willingness to discuss and counsel patients about cannabis, even if practitioner attitudes did not change.

Keywords: CBD; THC; medical therapy; pharmacology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics
  • Cannabinoid Receptor Agonists
  • Cannabis*
  • Dronabinol
  • Hallucinogens*
  • Humans
  • Medical Marijuana* / adverse effects
  • Nurse Practitioners*

Substances

  • Medical Marijuana
  • Dronabinol
  • Analgesics
  • Hallucinogens
  • Cannabinoid Receptor Agonists